Rainbow at shoreline

The Massachusetts ME/CFS & FM Association, a 501(c)3 founded in 1985, exists to meet the needs of patients with ME (Myalgic Encephalomyelitis), CFS (Chronic Fatigue Syndrome) or FM (Fibromyalgia), their families and loved ones. The Massachusetts ME/CFS & FM Association works to educate health-care providers and the general public regarding these severely-disabling physical illnesses. We also support patients and their families and advocate for more effective treatment and research.

This study is still recruiting patients as of October 2016.

This is a brain imaging study of pain responses. The study includes 5-14 assessment visits, lasting from 2-3 hours each. You may be eligible if you are 18-65 years old, are either generally healthy or have fibromyalgia, do not have a serious heart condition or certain other medical conditions, are not taking certain types of medications, and are not pregnant. There is no cost to you for any of the procedures and compensation up to $500.00 is provided.

For more details, see the study flyer.

The research takes place at the Brigham & Women’s Pain Management Center, 850 Boylston St, Chestnut Hill, and at the MGH Martinos Center
for Biomedical Imaging. For further information, please contact the study coordinator Olivia Franceschelli at 617-732-9718 or by email at ofranceschelli :at: partners.org.

Notice about names

The Massachusetts ME/CFS & FM Association would like to clarify the use of the various acronyms for Chronic Fatigue Syndrome (CFS), Chronic Fatigue & Immune Dysfunction Syndrome (CFIDS) and  Myalgic Encephalomyelitis (ME) on this site. When we generate our own articles on the illness, we will refer to it as ME/CFS, the term now generally used in the United States. When we are reporting on someone else’s report, we will use the term they use. The National Institutes of Health (NIH) and other federal agencies, including the CDC, are currently using ME/CFS. 

Massachusetts ME/CFS & FM Association changed its name in July, 2018, to reflect this consensus.